Azithromycin and SARS-CoV-2 infection: Where we are now and where we are going

J Glob Antimicrob Resist. 2020 Sep:22:680-684. doi: 10.1016/j.jgar.2020.06.016. Epub 2020 Jul 1.

Abstract

  1. •

    Azithromycin (AZM) is a promising drug candidate for the treatment of the COVID-19.

  2. •

    Studies so far on the use of AZM in COVID-19 patients have various methodological limitations.

  3. •

    The evidence on the efficacy of AZM as an adjunct to hydroxychloroquine for COVID-19 is not enough yet.

  4. •

    Combination of AZM and HCQ should be decided with caution due serious cardiac adverse effects.

  5. •

    Currently, 21 clinical trials are being carried out on the use of AZM in COVID-19.

Keywords: Azithromycin; COVID-19; Clinical trial; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2.

Publication types

  • Comment

MeSH terms

  • Azithromycin*
  • Betacoronavirus*
  • COVID-19
  • COVID-19 Drug Treatment
  • Coronavirus Infections* / drug therapy
  • Humans
  • Hydroxychloroquine
  • Pandemics*
  • Pneumonia, Viral*
  • SARS-CoV-2

Substances

  • Hydroxychloroquine
  • Azithromycin